Table 3.

Characteristics of responding patients

Patient no.Age/sexDiagnosisCytogeneticsPrior therapyDose level (MBq/kg)Response (duration, mo)
774/M2° AML after MDSComplex5-Aza (MDS)37PR (4)
1079/M2° AML, h/o APLder(7), t(1,7)ATO, SAHA (AML); ATRA, IDR/Ara-C × 3 (APL)37CR (9)
1180/MAML, M2 de novo 8None37CR (12)
1474/M2° AML after MDSNormalNone46.25PR (7)
1570/FAML, M2, relapsedNormalIDR/Ara-C × 346.25CRp (5)
1875/M2° AML after MDSdel(9q)Decitabine (MDS)37CRp (2)

Abbreviations: MDS, myelodysplastic syndrome; 5-Aza, azacitidine; ATO, arsenic trioxide; SAHA, vorinostat; ATRA, all-trans retinoic acid; IDR, idarubicin; Ara-C, cytarabine; APL, acute promyelocytic.